leucine has been researched along with Movement Disorders in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (50.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lerner, PP; Lerner, V; Miodownik, C | 1 |
| Cattepoel, S; Eckert, A; Kuehnle, K; Kulic, L; Nitsch, RM; Pagani, L; Rhein, V; Tracy, J; Wollmer, MA | 1 |
| Alp, MS; Aspey, BS; Harrison, MJ; Patel, Y | 1 |
| Cusick, PK; Ferrier, B; Haskell, BE; Koehler, KM | 1 |
| Bird, MT; Koestner, A; Reinglass, J; Shuttleworth, E | 1 |
| Barbeau, A; Kastin, AJ | 1 |
2 review(s) available for leucine and Movement Disorders
| Article | Year |
|---|---|
Tardive dyskinesia (syndrome): Current concept and modern approaches to its management.
Topics: Adrenergic beta-Antagonists; Adrenergic Uptake Inhibitors; alpha-Tocopherol; Amantadine; Anticonvulsants; Antioxidants; Antipsychotic Agents; Clonazepam; Dopamine Agents; Drugs, Chinese Herbal; Fatty Acids, Omega-3; Ginkgo biloba; Humans; Isoleucine; Isoxazoles; Leucine; Levetiracetam; Melatonin; Movement Disorders; Nootropic Agents; Piracetam; Plant Extracts; Propranolol; Pyridoxine; Resveratrol; Stilbenes; Tetrabenazine; Valine; Vitamins; Zonisamide | 2015 |
Effects of combined glutamate and platelet-activating factor inhibition on the outcome of focal cerebral ischaemia - an initial screening study.
Topics: Animals; Brain Ischemia; Cerebral Infarction; Drug Combinations; Glutamic Acid; Leucine; Male; Movement Disorders; Neuroprotective Agents; Periaqueductal Gray; Piperazines; Platelet Activating Factor; Platelet Membrane Glycoproteins; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, Cell Surface; Receptors, G-Protein-Coupled; Sodium Channel Blockers; Time Factors | 1997 |
4 other study(ies) available for leucine and Movement Disorders
| Article | Year |
|---|---|
Combined expression of tau and the Harlequin mouse mutation leads to increased mitochondrial dysfunction, tau pathology and neurodegeneration.
Topics: Adenosine Triphosphate; Age Factors; Animals; Apoptosis; Apoptosis Inducing Factor; Brain; Caspase 3; Electron Transport Complex I; Gene Expression Regulation; Genetic Predisposition to Disease; Humans; In Situ Nick-End Labeling; Leucine; Lipid Peroxidation; Male; Mice; Mice, Inbred C57BL; Mice, Mutant Strains; Mice, Transgenic; Mitochondria; Mitochondrial Diseases; Movement Disorders; Mutation; Nerve Degeneration; Nerve Tissue Proteins; Oxidative Stress; Proline; Proton Pumps; Silver Staining; Statistics, Nonparametric; tau Proteins; Tauopathies | 2011 |
The neurotoxicity of valine deficiency in rats.
Topics: Animals; Isoleucine; Leucine; Male; Movement Disorders; Nervous System; Rats; Red Nucleus; Tryptophan; Valine | 1978 |
The wobbler mouse mutant: an animal model of hereditary motor system disease.
Topics: Animals; Atrophy; Axonal Transport; Brain Stem; Chromosome Aberrations; Chromosome Disorders; Disease Models, Animal; Homozygote; Leucine; Lysosomes; Mice; Microscopy, Electron; Movement Disorders; Mutation; Nerve Tissue Proteins; Neurons; Spinal Cord; Tritium | 1971 |
Preliminary clinical studies with L-prolyl-L-leucyl-glycine amide in Parkinson's disease.
Topics: Administration, Oral; Aged; Amides; Antiparkinson Agents; Dihydroxyphenylalanine; Female; Glycine; Humans; Injections, Intravenous; Leucine; Male; Middle Aged; Movement Disorders; Parkinson Disease; Peptides; Proline | 1972 |